Roche’s Giredestrant NDA Accepted by FDA for Early Breast Cancer
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...
FLORENCE, Italy and NEW YORK, December 8, 2025 — The Menarini Group and its oncology subsidiary Stemline Therapeutics unveiled...
